On September 21, 2021 Astellas Venture Management LLC (President: Kazunori Maruyama, Ph.D, "AVM"), a wholly-owned venture capital subsidiary of Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas"), and Mission Bay Capital BioLabs ("MBC BioLabs"), a life-science incubator, reported their third collaboration on the "Future Innovator Prize" formerly known as Astellas Golden Ticket (Press release, Astellas Venture Management, SEP 21, 2021, View Source [SID1234590106]). Building on the success of the inaugural competition held in 2019, the Golden Ticket Competition offers entrepreneurial scientists or emerging biotechnology start-ups one year’s priority usage of MBC BioLabs’ state-of-the-art lab facility and access to Astellas’ research and development (R&D) capabilities and business leaders.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
With a shared commitment to discovering and advancing innovative science for the potential future benefit of patients worldwide, AVM and MBC BioLabs are continuing their partnership to support scientists and early-stage companies to accelerate their novel therapeutic programs, modalities or platforms.
"This is the third time we have worked with MBC BioLabs to identify emerging companies that can help us achieve and realize our VISION of turning innovative science into VALUE for patients," said Maruyama, President, AVM. "The combination of Astellas’ R&D expertise and the capabilities of MBC BioLabs allow start-ups to transform exciting ideas into real businesses that could bring value and hope to patients around the world."
"We are delighted to continue our partnership with Astellas," said Douglas Crawford, MBC BioLabs General Manager. "The outstanding work of the previous winners of these Future Innovator Prize competitions is testament to what can be achieved by pairing Astellas’ ongoing support, advice and expertise with our laboratory accelerator. I’m very excited about what the next collaboration will bring."
Entrepreneurial scientists, emerging life-science and biotechnology start-ups have until November 1, 2021 to enter the Golden Ticket Competition.
About the Future Innovator Prize at MBC BioLabs
Astellas is offering up to two Future Innovator Prizes for pioneering scientists with innovative research that complements Astellas’ areas of interest that fit with the Astellas Focus Area Approach and pipeline, including oncology, immunology, neuroscience including neuromuscular and sensory disorders.
Companies awarded an Astellas Future Innovator Prize will gain one year’s priority admission or renewal to MBC BioLabs’ state-of-the-art laboratory and access to Astellas’ R&D scientists and business leaders. The competition is open from September 21 to November 1, 2021. Entrepreneurial scientists, emerging life-science or biotechnology start-ups should submit their non-confidential company presentation, including a one-page executive summary, to View Source to be considered. The decision to award any Golden Ticket and the assessments underlying such decision, are solely within the judgment of Astellas and MBC BioLabs and are not subject to any objection or appeal.
The 2020 Astellas Golden Ticket winners were Keyhole Therapeutics, Inc. and Jupiter Therapeutics, Inc., chosen for the potential of their innovations to deliver therapeutic advances for unmet medical needs and their potential synergy with Astellas’ Focus Area Approach.
For further information, please go to: View Source, where you can also find submission guidance for your non-confidential company presentation and executive summary.